Amgen Inc. vs The Boeing Company: Strategic Comparison

This in-depth comparison examines Amgen Inc. and The Boeing Company across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Amgen Inc. on its own, evaluating The Boeing Company, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Amgen Inc. and The Boeing Company is widest.

On the headline numbers, Amgen Inc. reports annual revenue of $36.8B against $89.5B for The Boeing Company, while their respective market capitalizations stand at $228.2B and $148.0B. Both Amgen Inc. and The Boeing Company are headquartered in United States, so they compete in a shared home market and regulatory environment.

Amgen Inc.: Amgen is one of the companies that created the biotechnology industry. Instead of synthesizing small-molecule drugs, it engineers living cells to make complex proteins, an approach it first commercialized with Epogen in 1989. Based in Thousand Oaks, California, it is best known for medicines in bone health, inflammation, cardiovascular disease and kidney disease, and since the 2023 Horizon acquisition in rare disease. Fiscal 2025 revenue was US$36.8 billion across a portfolio in which 14 products each sold more than US$1 billion, although several of the older brands are now losing both price and volume.

The Boeing Company: Boeing is the largest U.S. aerospace company by revenue and one half of the commercial jet duopoly with Airbus. It builds the 737 MAX, 767, 777/777X and 787 Dreamliner; military aircraft such as the F-15EX, F/A-18, KC-46A, P-8, AH-64 Apache and CH-47 Chinook; and space systems including the SLS core stage and commercial satellites. Since 2019 its story has been shaped by safety failures, from the two fatal 737 MAX crashes to the January 2024 Alaska Airlines door-plug blowout, and by a slow recovery led since August 2024 by CEO Kelly Ortberg.

Amgen Inc. and The Boeing Company pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Amgen Inc. and The Boeing Company.

Amgen Inc. business model: Amgen operates a high-risk, high-reward biopharmaceutical business model. It spends heavily on research to discover and engineer new biologic drugs: US$7.3 billion in fiscal 2025, or 20.7% of product sales. Once a drug is approved by the FDA, Amgen secures a patent, granting them a temporary monopoly to sell the drug at a premium price. Because biologic drugs are grown from living cells rather than chemically synthesized, they are much harder for competitors to copy, resulting in slightly longer and more defensible monopolies than traditional pills.

The Boeing Company business model: Boeing earns money in three segments. Commercial Airplanes (BCA) designs, builds and sells the 737, 767, 777 and 787. Airlines and lessors pay deposits and progress payments over several years, but most of the price arrives at delivery, so revenue moves with delivery volume. BCA had $41.5 billion of FY2025 revenue and still lost $7.1 billion from operations, largely because of $5.3 billion of 777X and 767 reach-forward losses. Defense, Space & Security (BDS) sells fighters, tankers, helicopters, satellites and space systems to the U.S. government and allies under a mix of cost-plus and fixed-price contracts, bringing in $27.2 billion. Global Services (BGS) sells parts, maintenance, modifications and training to more than 13,000 Boeing commercial jets in service plus military fleets. It is the steady earner: $20.9 billion of 2025 revenue and an 18.1% operating margin in the first half of 2026.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Amgen Inc. stack up against those of The Boeing Company.

Amgen Inc. competitive advantage: Amgen's main competitive advantage is experience making complex biologics at commercial scale, which it has done continuously since Epogen launched in 1989. Producing a glycosylated protein or a monoclonal antibody to a consistent specification requires validated facilities, process know-how and a regulatory record that take years to build, which is also why the company can turn the same capability toward biosimilars of competitor products. Its balance sheet lets it buy late-stage assets rather than rely only on internal discovery: Onyx, Otezla, Five Prime, ChemoCentryx and Horizon together cost about US$57 billion between 2013 and 2023.

The Boeing Company competitive advantage: Boeing's advantages are hard to copy: a century of certification know-how, a global installed fleet that keeps buying parts and services, and a backlog of more than 6,200 commercial airplanes worth $597 billion at June 30, 2026. Only Airbus builds comparable large jets, and with both makers sold out for years, airlines that need aircraft this decade order from both. In defense, Boeing now holds both U.S. sixth-generation fighter programs, the Air Force F-47 (March 2025) and the Navy F/A-XX (September 2026).

Future prospects matter as much as current results. The growth strategies below explain how Amgen Inc. and The Boeing Company each plan to expand from here.

Amgen Inc. growth strategy: Amgen's growth plan has two parts: scale the newer medicines and buy what the pipeline does not supply. Recent launches and acquired products drove the 10% revenue growth in fiscal 2025, with Tezspire up 52% to US$1.48 billion, Repatha up 36% to US$3.02 billion, Evenity up 34% to US$2.10 billion, Uplizna up 73% to US$655 million and Imdelltra reaching US$627 million in its second year. The company is pushing into obesity with MariTide, now in six Phase 3 MARITIME studies, and runs a biosimilars business that produced about US$3.0 billion of fiscal 2025 sales across Pavblu, Mvasi, Amjevita and Wezlana.

The Boeing Company growth strategy: Under Kelly Ortberg the plan is to stabilize first and grow second. Boeing runs a Safety & Quality Plan with key performance indicators for each factory and raises 737 and 787 rates only when those metrics and the FAA allow it. It brought fuselage production back in-house by closing the Spirit AeroSystems acquisition in December 2025, sold non-core digital businesses for $10.55 billion to cut debt, and is investing in North Charleston for higher 787 output and in St. Louis for fighter production. For its next new airplane, Boeing says it is designing the production system alongside the aircraft.

A closer look at the financial trajectory of Amgen Inc. and The Boeing Company rounds out the comparison.

Amgen Inc.: Amgen is a cash-generative business with high product gross margins. In fiscal 2025 it reported US$36.8 billion of total revenues, US$7.7 billion of GAAP net income, a 25.8% GAAP operating margin, US$8.1 billion of free cash flow and US$5.1 billion of dividends paid. Its results used to depend on a few large franchises, first Epogen and Aranesp, then Enbrel. As those matured Amgen bought revenue instead: Onyx in 2013, Otezla in 2019 and Horizon Therapeutics for US$27.8 billion in 2023. That last deal is also the main reason for the balance sheet it now carries, with US$54.6 billion of debt outstanding at December 31, 2025, debt leverage of about 3.2 times EBITDA and US$2.8 billion of net interest expense in fiscal 2025.

The Boeing Company: Boeing went from record revenue of $101.1 billion and a $10.5 billion profit in 2018 to six straight years of losses after the 737 MAX grounding, the pandemic, the 2024 door-plug blowout and a 53-day machinists' strike. The 2024 loss alone was $11.8 billion. To protect its investment-grade rating, Boeing raised about $24 billion of equity in October 2024 and sold Jeppesen, ForeFlight and other digital aviation assets to Thoma Bravo for $10.55 billion in 2025. FY2025 revenue rose 34% to $89.5 billion and net earnings returned to $2.2 billion, but that profit came from the $9.6 billion sale gain; Commercial Airplanes still lost $7.1 billion. In the first half of 2026 revenue rose 11% to $46.8 billion, the net loss narrowed to $435 million, and consolidated debt fell to $45.9 billion from $54.1 billion at the end of 2025.